Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy.
Publication/Presentation Date
10-1-2019
Abstract
BACKGROUND: Anthracycline cardiomyopathy contributes to the morbidity and mortality of cancer survivors but long-term data are lacking. This study sought to describe the phenotype of long-term anthracycline cardiomyopathy, the prevalence of myocardial fibrosis and its association with cardiac remodeling, systolic function and clinical outcomes.
METHODS AND RESULTS: We undertook contrast-enhanced CMR in 81 cancer survivors at median 5 years after anthracycline (mean dose 279 SD 89 mg/m
CONCLUSIONS: Long-term anthracycline cardiomyopathy is characterized by pathologically increased iLVESV. Both LGE and elevated native T1 measurements were associated with significant adverse cardiac remodeling and reduced systolic function, and the latter with heart failure hospitalizations.
Volume
292
First Page
248
Last Page
252
ISSN
1874-1754
Published In/Presented At
Harries, I., Biglino, G., Baritussio, A., De Garate, E., Dastidar, A., Plana, J. C., & Bucciarelli-Ducci, C. (2019). Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy. International journal of cardiology, 292, 248–252. https://doi.org/10.1016/j.ijcard.2019.04.026
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31006597
Department(s)
Administration and Leadership
Document Type
Article